No Data
No Data
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), GeneDx Holdings (WGS) and Teva Pharmaceutical (TEVA)
Crinetics Pharmaceuticals (CRNX) Gets a Buy From Piper Sandler
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
Express News | Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)